The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.

To manage the finances of CAR-T therapies, which can cost up to $1 million each, health systems are increasingly using “pay for performance” deals, according to a Nov. 17 article in Specialty Pharmacy ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

PHILADELPHIA, PA — Vittoria Biotherapeutics, Inc. announced it will present interim clinical data from its first-in-human ...

GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...

Following her ask for advice on navigating the symptoms of Hypermobile Ehlers-Danlos syndrome, a genetic disorder primarily ...

It’s really fun,” said Dylan Aristy Mota, thrilled that he got a chance at the rite of childhood — thanks to doctors ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.

Tucked away in the mountain town of Franklin, North Carolina, the Whistle Stop Shop Depot isn’t just another antique store—it’s a time-traveling adventure where your wallet stays surprisingly full ...

Basic research may seem far removed from everyday technology, yet it often provides the spark for major industrial shifts.

Making biotech more diverse and fair is a big deal, fixing past mistakes and making sure everyone has a chance to be involved ...